ELEKTA AB (publ) Corporate registration number 556170-4015 Kungstensgatan 18 – Box 7593 – SE 103 93 Stockholm

Nine-month interim report May – January 2007/08

Order bookings rose 5 percent to SEK 3,701 M (3,539). Based on unchanged exchange rates order bookings rose 10 percent. Order backlog January 31, 2008 was at an all time high level of SEK 4,581 M.
Net sales rose 7 percent to SEK 3,285 M (3,082). Based on unchanged exchange rates net sales rose 11 percent.
Operating profit rose 9 percent to SEK 267 M (246) and operating margin was 8 percent (8).
Profit after taxes was SEK 174 M (183). Profit per share after dilution was SEK 1.91 (1.95).
Cash flow from operating activities improved by SEK 187 M to positive SEK 89 M (neg. 98). Cash flow after investments was negative SEK 35 M (neg. 324). Acquisitions were included with SEK 95 M (144).
Recognizing the challenge in delivering high volumes in the fourth quarter, Elekta reiterates the full year outlook of net sales growth in local currency over 12 percent and operating profit growth of 25-30 percent.
Elekta AB (publ) Nine-month interim report May January 2007/08 1 • In March, Elekta concluded the acquisition of CMS, a leader in the development, sales and support of advanced radiation therapy planning solutions, for a total cash consideration representing an enterprise value of USD 75 M.

President & CEO Tomas Puusepp comments:

"In the third quarter of fiscal year 2007/08, we saw a continued strong demand. Order intake for the first 9 months increased by 10 percent in local currency, driven primarily by a continued success in radiation therapy in North America, a stronger interest in Leksell Gamma Knife® in Europe and a strong recovery on the Chinese market. Order bookings for the third quarter in isolation, shows moderate growth in local currency, explained by the large European orders that were received in the comparison quarter.

On the market for linear accelerator systems, Elekta continues to gain market share, primarily as a result of significantly larger volumes to North America, where Elekta's technology for image guided radiation therapy together with the strength in the Elekta-IMPAC combination, is resulting in Elekta gaining many new customers.

The smaller markets where Elekta sells its products through distributors are more volatile. So far during this fiscal year, we have seen fewer orders from the distributor markets, while we at the same time have a strong pipeline for Q4 and onwards.

Demand for Elekta's software systems, primarily marketed under the IMPAC brand, remains on a high level. However, with more business to medical oncology and to non-English speaking countries, the installation and adaptation processes are prolonged. In the third quarter, this resulted in lower net sales and slightly lower operating result than expected. In the forth quarter, we expect to complete installations, and thus recognize revenue, for a large number of software projects.

On the market for radiosurgical treatment of brain disorders, Leksell Gamma Knife is holding a strong position. Leksell Gamma Knife® Perfexion™ is a significant improvement to its users both in terms of number of treatable patients as efficiency in the treatment process. For this fiscal year, I expect that the number of delivered Leksell Gamma Knife units will increase by over 30 percent with the growth coming predominantly from the European market. A large majority of these deliveries are Leksell Gamma Knife Perfexion.

Thanks to the enhanced and unique capabilities of Leksell Gamma Knife Perfexion, we have the opportunity to address new clinical applications and position Gamma Knife surgery among other modalities also within conventional radiation oncology.

A milestone in the development of Elekta is the acquisition of CMS and I am very pleased that we could complete this process according to plan. Short term it means a stronger more comprehensive product portfolio. In a longer perspective, it dramatically strengthens our ability to develop advanced software systems for radiation therapy planning. This acquisition is fully in line with our acquisition and collaboration strategy and significantly strengthens our ability to address the entire radiation therapy value chain.

The operating result for the 9 months period increased by 9 percent, which indicate an underlying (taken currency effects in consideration) improvement of about 26 percent. On a rolling 12 months basis operating margin was 11 percent.

Business already in the backlog together with contracts for delivery in April 2008 where we right now are firming up shipment schedules, sums up to the expectation that we will see high delivery volumes in the fourth quarter. This is expected to result in a net sales growth of 20 percent (in local currency) for the fourth quarter in isolation.

I am confident in our capacity to carry out these high volumes according to plan. However, we are dependent on customers being able to accept delivery in the agreed timeframe.

Based on the high expected delivery volumes in the fourth quarter and resulting high operational margins, I expect that Elekta will grow net sales this year by over 12 percent in local currency and improve operating profit with 25-30 percent.

Elekta's operations

Elekta is an international medical technology group, providing oncologists, radiation therapists, neurosurgeons and many other medical specialists with state of the art tools to fight serious disease. Elekta's solutions are used at over 4,500 hospitals globally to treat cancer with radiation therapy, to diagnose and treat brain disorders as well as to run efficient and effective clinical practices. Elekta is the world leader in image guided and stereotactic clinical solutions for radiosurgery and radiation therapy, methods for aggressively treating tumors and functional targets with ultrahigh precision while sparing healthy tissue. Through ambitious Research & Development programs and close collaborations with clinical partners, Elekta continues to launch groundbreaking new technology at a rapid pace. All of Elekta's solutions employ non-invasive or minimally invasive techniques, which are clinically effective, yet cost-effective and gentle to the patient.

Market outlook

The total market for Elekta's clinical solutions, IT systems and services is expected to grow by 5-10 percent annually and the unmet needs remain high. However, the high value of individual orders and the particularities of the healthcare industry market often lead to significant quarterly variations in business volume, product mix and geographical mix.

The market development is driven by the shortage of treatment capacity that is prevailing in most countries and by the increase in number of cancer cases, a result of higher life expectancy and better diagnostics. New advanced, more precise and accurate methods are expected to increase the role of radiation therapy in the future. The rapid development of new technology is resulting in higher average order values. An increasing number of customers are requesting more comprehensive and long-term relationships with suppliers.

In virtually all countries, health care systems are under strong pressure to improve efficiency and at the same time slow down cost expansion. Software systems for higher efficiency, in patient throughput as well as information management and administration, becomes more critical for operations and the demand is increasing.

Significant events

In January, Elekta announced a Letter of Intent to acquire CMS, a worldwide leader in the development, sales and support of advanced radiation therapy planning solutions, for a total cash consideration representing an enterprise value of USD 75 M. The purchase agreement was signed in February and the transaction was concluded on March 4. This is a highly complementary acquisition for Elekta, with strategic value from several perspectives:
o CMS portfolio of advanced and established software systems for radiation therapy planning significantly strengthens the total radiation therapy customer offering from Elekta.
o CMS, with several leading solutions in clinical use and a strong pipeline of advanced functionality in development, will significantly contribute to Elekta's strategy in radiation therapy planning and will enable Elekta to accelerate the development of new solutions as well as bring these to market more quickly and effectively.
o Through the acquisition of CMS, about 1,000 new radiation therapy departments are added to the customer list of the Elekta Group.
o CMS is also the market leader in treatment planning for proton therapy and the acquisition will reinforce Elekta's leadership in software systems for proton therapy facilities and strengthen the collaboration between Elekta and its current partners in this area.
o The acquisition is expected to result in an accretion to earnings on a cash basis in fiscal year 2008/09 and onwards, a neutral effect on EPS in fiscal year 2008/09 and accretion thereafter.
In January, Elekta became the first supplier to release a commercially available solution for volumetric intensity modulated arc therapy (VMAT). The two main benefits of this unique Elekta technology promise to significantly reduce treatment time combined with improved conformance to the target and sparing of dose to adjacent healthy tissues. The first hospitals to treat patients with this groundbreaking technology were The Royal Marsden Hospital in Sutton UK and Allgemeines KrankenHaus / Medical University of Vienna in Austria.
In December Elekta received an order valued at close to 5 million Euro from CHU (University Hospital Center) de Poitiers. The hospital has selected Elekta as the main partner in an ambitious program to improve radiation therapy treatment capacity in the Poitou-Charente region and is replacing equipment from a different vendor with three Elekta Synergy® digital linear accelerator systems for intensity modulated and image guided radiation therapy.
In January ProCure Treatment Centers, Inc. announced that it has selected IMPAC Medical Systems, an Elekta Company, as a preferred provider of oncology information systems for its IBAequipped proton beam therapy centers. ProCure designs, builds and operates proton therapy facilities in partnership with local radiation oncologists and community hospitals.
During January and February, 2008, Elekta has repurchased 951,300 B shares at an average price of SEK 105.11 totaling SEK 99,992,816. The Board intends to propose to the next AGM that these shares should be cancelled.

Order bookings and order backlog

Order bookings rose 5 percent to SEK 3,701 M (3,539). Based on unchanged exchange rates order bookings rose 10 percent.

Based on unchanged exchange rates order bookings in North and South America rose 19 percent, region Europe including Middle East and Africa declined by 4 percent and Asia rose 21 percent.

Order bookings during the third quarter declined by 1 percent to SEK 1,229 M (1,237).

Order backlog January 31, 2008 was at an all time high level of SEK 4,581 M compared to SEK 4,247 M on April 30, 2007.

Order bookings	Quarter 3	Quarter 3 Change		9 months	9 months Change			Rolling Change
SEK M	2007/08	2006/07		2007/08	2006/07		12 months
Europe, Middle East, Africa	521	664	-22%	1,370	1,465	-6%	1,902	-9%
North and South America	609	470	30%	1,713	1,531	12%	2,489	12%
Asia	99	103	-4%	618	543	14%	873	12%
Group	1,229	1,237	-1%	3,701	3,539	5%	5,264	4%

Market comments

North and South America

The North American market continues to show solid growth, primarily driven by the rising cancer incidence and by the rapid acceptance of new and refined treatment methods such as image guided radiation therapy (IGRT), stereotactic radiation therapy (SRT) and the new VMAT functionality for dynamic arc treatments.

Elekta is leading the development in advanced methods for radiation therapy and radiosurgery and continues to improve market shares in North America. The introduction of Elekta Infinity™ and the VMAT technology, which has met strong interest, has the potential to reduce treatment times and thereby improve patient throughput as well as clinical effectiveness.

In the US market, efficiency in patient flows and processing of clinical data are often decisive sales arguments. Software systems that handle both the entire treatment process and administration and resource allocation are therefore in most cases an integrated part of the delivery of treatment systems. MOSAIQ™, the new system from Elekta for EMR, workflow and information management, are now being installed at new and existing customers at a rapid pace at both radiation oncology and medical oncology centers.

Europe including Middle East and Africa

Elekta's position in the European market for radiation therapy is strong. The market development is to a large extent driven by national and regional initiatives to remedy the lack of care capacity and therapeutic equipment. In many European countries, the number of linear accelerators per capita is less than half that of the US.

Elekta's ability to provide comprehensive and integrated solutions, yet based on industry standards and open connectivity, makes the company an attractive partner in tenders involving comprehensive long-term commitments.

The UK government has recently announced an ambitious plan for preventing cancer and boost treatment capacity in England. In total GBP 400 M will be invested over the next 10 years, and a significant portion of these investments will be for radiation therapy equipment.

Asia

There is a solid rationale for a continued long-term market growth in Asia. The number of linear accelerators per capita is low, in an international comparison. Through the introduction of Elekta Compact™, Elekta will be able to offer solutions across the spectrum of price and performance and is well positioned to meet continued strong demand in the region and to support health care providers in these countries in their quest to develop cancer care.

In China, the healthcare system is currently undergoing reform and restructuring, in order to meet the growing need for advanced care and to make these services more accessible to a larger share of the population.

In Japan, there is a large installed base of Leksell Gamma Knife and subsequently, there is substantial potential for upgrades to Leksell Gamma Knife Perfexion. Due to the long process for regulatory approval in Japan, Elekta expects to be able to introduce this new system late in the fiscal year 2007/08.

CMS is the market leader in Japan on the market for radiation therapy planning, which will facilitate for Elekta to address new customers.

After market

Elekta's aftermarket is continuing to show favorable development, partly as a result of a growing installed base. The shift towards more advanced, newly launched systems is resulting in more customers choosing comprehensive and long term service agreements.

Elekta continues to focus on further development of support and lifecycle business and on providing value-based services to the expanding customer base.

Net sales

Net sales rose 7 percent to SEK 3,285 M (3,082). Based on unchanged exchange rates net sales increased by 11 percent.

Net sales during the third quarter rose by 3 percent to SEK 1,097 M (1,068).

Net sales	Quarter 3	Quarter 3 Change		9 months	9 months Change		12 months
SEK M	2007/08	2006/07		2007/08	2006/07		2006/07
Europe, Middle East, Africa	378	439	-14%	1228	1221	1%	1,840
North and South America	411	428	-4%	1354	1293	5%	1,933
Asia	308	201	53%	703	568	24%	752
Group	1,097	1,068	3%	3,285	3,082	7%	4,525

Earnings

Operating profit increased by 9 percent to SEK 267 M (246), positively impacted by the increased net sales but negatively by currency impacts and higher expenses. The expense increase is primarily attributable to new entities.

Gross margin amounted to 41 percent (41) and operating margin to 8 percent (8).

Operating profit during the third quarter amounted to SEK 72 M (87) and operating margin was 7 percent (8). The profit for the quarter was negatively impacted by lower net sales of software. On a rolling 12 months basis operating margin was 11 percent.

Calculated IFRS 2 costs for Elekta's outstanding option program amounted to SEK 14 M (25).

Investments in research and development rose 10 percent to SEK 299 M (271) equal to 9 percent (9) of net sales. Capitalization of development costs and amortization of capitalized development costs affected earnings by SEK 21 M (8). Capitalization amounted to SEK 37 M (17) and amortization to SEK 16 M (9).

Exchange rate effects on operating profit compared with previous year:

Exchange rate movements affected operating profit before recorded exchange differences negatively by SEK 62 M.
Recorded exchange gains in operations amounted to SEK 27 M.
Recorded exchange gains in operations preceding year was SEK 9 M.

In total, exchange rate fluctuations affected the operating profit for the nine months period, compared with previous year, negatively by SEK 44 M.

Currency hedging is done on the basis of anticipated sales in foreign currency over a period of up to 24 months. Exchange rate losses from forward contracts in operating profit amounted to SEK 4 M (gains 48). Unrealized exchange rate gains from cash flow hedges amounted to SEK 7 M and are reported in shareholders' equity taking into account the tax impact.

Net financial items amounted to an expense of SEK 11 M (income 8). Net interest expenses amounted to SEK 28 M (expense 18). Income from participations in associated companies amounted to SEK 6 M (19) and financial currency exchange gain was SEK 11 M (gain 7).

Profit after net financial items amounted to SEK 256 M (254). Calculated tax expense amounted to SEK 82 M or 32 percent. Profit after taxes amounted to SEK 174 M (183).

Earnings per share amounted to SEK 1.92 (1.96) before dilution and SEK 1.91 (1.95) after dilution.

Return on shareholders' equity was 19 percent (18) and return on capital employed totaled 21 percent (18).

Investments and depreciation

Acquisition of 3D Line resulted in an increase of intangible and tangible fixed assets of SEK 149 M. Other investments in intangible and tangible fixed assets amounted to SEK 73 M (107). Amortization of intangible and depreciation of tangible fixed assets amounted to SEK 131 M (101).

Liquidity and financial position

Cash flow from operating activities was positive and amounted to SEK 89 M (neg. 98). The improvement is related to improved operating cash flow but compared to the same period previous year also a lower increase in tied up working capital. Cash flow after investments was negative SEK 35 M (neg. 324). Acquisition was included with SEK 95 M (144).

Liquid funds amounted to SEK 172 M compared to SEK 484 M April 30, 2007. Of total bank balances SEK 2 M were pledged, primarily for commercial guarantees.

Interest-bearing liabilities totaled SEK 910 M compared with SEK 987 M on April 30, 2007. Net debt amounted to SEK 738 M compared with SEK 503 M on April 30, 2007.

Net debt/equity ratio was 0.42 and equity/assets ratio was 33 percent.

During May-January 2007/08, 108,540 new Series B shares were subscribed through exercise of warrants distributed within the framework of the established option programs.

During the period January 24 through February 8, 2008, Elekta has repurchased 951,300 B shares at an average price of SEK 105.11 totaling SEK 100 M. Elekta's current holding of own shares thereby amounts to 2,582,171 B shares. The Annual General Meeting on September 25, 2007, resolved to cancel 1,630,871 of these shares and the cancellation process has started. The Board intends to propose to the next AGM that the recently repurchased 951,300 shares also should be cancelled.

Total number of shares on February 29, 2008 was 93,904,516 of which 3 562 500 Series A shares and 90,342,016 Series B shares.

Employees

The average number of employees was 2,057 (1,916), of which BMEI and 3D Line employed 161 (88).

The number of employees on January 31, 2008 totaled 2,102 compared with 2,031 on April 30, 2007.

Parent Company

The operations of the Parent Company include Group management, joint Group functions and financial management. The Parent Company's profit after financial items amounted to SEK 339 M (loss 25), positively impacted by dividends from subsidiaries. The average number of employees was 21 (20).

Acquisition of 3D Line

On May 3, 2007, Elekta acquired 3D Line Research and Development S.r.l. (3D Line), adding to Elekta a highly qualified R&D group specialized in stereotactic radiosurgery and dynamic IMRT treatments as well as a product portfolio of advanced equipment and treatment planning software systems for performing radiation therapy with high precision and optimized dose distribution.

3D Line's registered office is in Milan, Italy and at time of acquisition 3D Line had 20 employees.

In May, Elekta paid 10 million Euro in cash for 3D Line. The purchase agreement contains also an earn-out maximized to 8 million Euro, dependent on the company's performance during the coming 3 years. Acquisition cost amounts to SEK 3 M.

The initial accounting for the fair values to be assigned to the acquired unit's identifiable assets and liabilities has been provisionally established. Intangible assets and goodwill have been valued at SEK 148 M. The intangible assets consist of technology and the amortization period is 6 years. Goodwill refers primarily to future synergy effects.

The transaction structure is to fully integrate 3D Line's organization as well as products and service into those of the Elekta Group. The revenue directly attributable to the company's current products was marginal during the reported period and as planned, leading to an operating loss. The positive financial effects of the acquisition will therefore start to emerge over time and the acquisition is forecasted to be financially neutral during Elekta's current fiscal year and accretive thereafter. In addition to the direct financial effects from its existing products, 3D Line's technologies and expertise will have immediate positive effects on products under development within the Elekta Group.

Acquisition of CMS

On March 4, 2008, Elekta acquired CMSI Holdings Corp. including its subsidiary CMS Inc. for a total cash consideration representing an enterprise value of USD 75 M.

CMS is a worldwide leader in the development, sales and support of advanced radiation therapy dose planning solutions, supporting over 1,500 sites in clinical operation throughout the world. CMS will significantly contribute to Elekta's strategy in radiation therapy dose planning. Further CMS is the market leader in treatment dose planning for proton therapy with eight installations in clinical use. Integrating these solutions with the MOSAIQ™ information management system will reinforce Elekta's leadership in software systems for proton therapy facilities and strengthen the collaboration between Elekta and its current partners in this area.

CMS is based in St Louis, Missouri, USA. The group has about 300 employees worldwide.

Risks and uncertainties

Elekta's ability to deliver treatment equipment is, to a large extent, dependent on customers being able to accept delivery in the agreed timeframe, which results in a risk of delayed deliveries and corresponding delayed revenue recognition. In its operations, Elekta is subject to a number of financial risks, primarily related to exchange rate fluctuations.

Description of other risks and uncertainties in Elekta's business can be found in the annual report 2006/07 on page 38-39 and in note 2. Nothing essential has happened to change the risks described therein.

Future prospects for fiscal year 2007/08 – remains unchanged

Demand for Elekta's clinical solutions, products and services remains strong. The order backlog is on a record high level. The product portfolio is more comprehensive and more competitive than ever before.

During the fourth quarter, high delivery volumes are expected for linear accelerator systems and Leksell Gamma Knife units, as well as software systems. This is expected to result in a net sales growth for the quarter in isolation of 20 percent in local currency. Elekta has the capacity to carry out these deliveries according to plan, while being dependent of customers' ability to accept delivery in the agreed timeframe.

Consequently, Elekta reiterates the outlook for fiscal year 2007/08 of a net sales growth of over 12 percent in local currency and an operating profit to growth of 25-30 percent.

Financial information

The year-end report on operations in 2007/08 will be published on June 16, 2008.

Stockholm March 10, 2008

Elekta AB (publ)

Tomas Puusepp President and CEO

The Company's auditors have not reviewed this interim report

For further information, please contact:

Peter Ejemyr, Group Vice President Corporate Communications, Elekta AB (publ) Tel: +46 733-611 000 (mobile), e-mail: [email protected] For more information on Elekta, please visit www.elekta.com

Teleconference

In connection with this report, a teleconference will be held on March 10, at 15.00 (3 p.m) Swedish time (GMT+1).

Call-in numbers:

Sweden:	+46 (0)8 5052 0110
UK:	+44 (0)20 7162 0025
US:	+1 334 323 6201
France:	+33 (0)1 7099 3208
Germany:	+49 (0)695 8999 0507
Netherlands:	+31 (0)20 7965 008
Switzerland:	+41 (0)434 5692 61
Denmark:	+45 3271 4607

Please note: for Local Connect dial-in numbers – it may be required to dial the area code to enter the conference. To take part in the conference call, please dial in about 5 minutes in advance. You will be placed in a so-called waiting room until the operator has declared the meeting opened.

Instant replay: The teleconference will be available on instant replay for 7 days. To obtain the service, please dial U.K. (Europe): +44 (0) 20 7031 4064, U.S: +1 954 334 0342, Sweden +46 (0)8 5052 0333. Access code: 783032.

The March 10 teleconference will also be broadcasted over the Internet (audio only). Please visit http://www.elekta.com/investors and follow the link or use the direct link: http://wcc.webeventservices.com/view/wl/r.htm?e=103507&s=1&k=FD0B7FDC14CB7FCF7643 84B7DF3BA9DF&cb=genesys

Accounting principles

This interim report has been prepared in accordance with the Annual Accounts Act, IAS 34 Interim Financial Reporting and the Swedish Financial Accounting Standards Council's recommendation RR 31 Interim Reporting for Groups and, with regard to the Parent Company, RR 32 Accounting for legal entities. Applied accounting principles and calculation methods are in accordance with the Annual Report for 2006/07.

Exchange rates		Average rate			Closing rate
		May-Jan.	May-Jan. Change		Jan. 31,	Apr. 30, Change
Country	Currency	2007/08	2006/07		2008	2007
Euro	1 EUR	9.295	9.193	1%	9.436	9.159	3%
Great Britain	1 GBP	13.359	13.580	-2%	12.630	13.423	-6%
Japan	100 JPY	5.724	6.164	-7%	5.955	5.635	6%
United States	1 USD	6.631	7.173	-8%	6.358	6.738	-6%

CONSOLIDATED INCOME STATEMENT

	3 months Nov. - Jan.	3 months Nov. - Jan.	9 months May - Jan.	9 months May - Jan.	12 months Feb. - Jan.	12 months May - Apr.
SEK M	2007/08	2006/07	2007/08	2006/07	2007/08	2006/07
Net sales Cost of products sold	1,097 -666	1,068 -628	3,285 -1,926	3,082 -1,807	4,728 -2,767	4,525 -2,648
Gross income	431	440	1,359	1,275	1,961	1,877
Selling expenses	-164	-159	-486	-450	-649	-613
Administrative expenses	-120	-111	-355	-325	-460	-430
R&D expenses	-87	-91	-278	-263	-375	-360
Exchange differences in operation Operating profit	12 72	8 87	27 267	9 246	53 530	35 509

Result from participations in associated companies	3	9	6	19	4	17
Interest income	7	10	27	34	39	46
Interest expenses	- 17	- 18	-55	-52	-74	-71
Financial exchange differences	5	6	11	7	10	6
Income after financial items	70	94	256	254	509	507
Taxes	- 22	- 15	-82	-71	-172	-161
Net income	48	79	174	183	337	346
Attributable to
Parent Company shareholders	49	80	177	184	341	348
Minority shareholders	- 1	- 1	- 3	- 1	- 4	- 2
Earnings per share before dilution	0.54	0.85	1.92	1.96	3.68	3.72
Earnings per share after dilution	0.53	0.84	1.91	1.95	3.66	3.70
CASH FLOW
Operating cash flow	72	109	265	241	509	485
Change in working capital	-123	-56	-176	-339	-172	-335
Cash flow from operating activities	-51	53	89	-98	337	150
Investments and disposals	-6	-34	-124	-226	-155	-257
Cash flow after investments	-57	19	-35	-324	182	-107
External financing	-122	-26	-278	-251	-400	-373
Change in liquid funds	-172	-18	-312	-587	-222	-497

CONSOLIDATED BALANCE SHEET

	Jan. 31,	Jan. 31,	April 30,
SEK M	2008	2007	2007
Intangible assets	2,220	2,247	2,198
Tangible fixed assets	222	254	252
Shares and long-term receivables	36	36	32
Deferred tax assets	14	28	14
Inventories	613	500	423
Receivables	1,945	1,718	1,953
Liquid funds	172	394	484
Total assets	5,222	5177	5,356
Shareholders' equity	1,743	1,842	1,863
Interest-bearing liabilities	910	1,016	987
Interest-free liabilities	2,569	2,319	2,506
Total shareholders' equity and liabilities	5,222	5,177	5,356
Assets pledged	2	11	9
Contingent liabilities	89	100	89

CHANGES IN SHAREHOLDERS' EQUITY

SEK M	Jan. 31, 2008	Jan. 31, 2007	April 30, 2007
Opening balance	1,863	1,868	1,868
IFRS 2 cost and deferred tax	12	18	18
IAS 39 unrealized cash flow hedges	-8	7	6
Translation differences	-98	-63	-106
Net income	174	183	346
Option premiums and warrants exercised	7	15	16
Repurchase of shares	-123	-100	-200
Dividend	-92	-94	-93
Minority's capital contribution	8	8	8
Closing balance	1,743	1,842	1,863

KEY FIGURES	12 months May - Apr. 2004/05*	12 months May - Apr. 2005/06	12 months May - Apr. 2006/07	9 months May - Jan. 2006/07	9 months May - Jan. 2007/08

Order bookings, SEK M	3,558	4,705	5,102	3,539	3,701
Net sales, SEK M	3,152	4,421	4,525	3,082	3,285
Operating result, SEK M	364	453	509	246	267
Operating margin	12%	10%	11%	8%	8%
Profit margin	12%	10%	11%	8%	8%
Shareholders' equity, SEK M	1,694	1,868	1,863	1,842	1,743
Capital employed, SEK M	2,527	2,959	2,850	2,858	2,653
Equity/assets ratio	38%	35%	35%	36%	33%
Net debt/equity ratio	0.05	0.06	0.27	0.34	0.42
Return on shareholders' equity **	16%	17%	19%	18%	19%
Return on capital employed **	21%	18%	20%	18%	21%

* Restated according to IFRS.

** Based on rolling 12 months.

DATA PER SHARE	12 months	12 months	12 months	9 months	9 months
	May - Apr.	May - Apr.	May - Apr.	May - Jan.	May - Jan.
	2004/05*	2005/06	2006/07	2006/07	2007/08

Earnings per share
before dilution, SEK	2.69	3.23	3.72	1.96	1.92
after dilution, SEK	2.69	3.21	3.70	1.95	1.91
Cash flow per share
before dilution, SEK	-11.09	1.68	-1.14	-3.45	-0.38
after dilution, SEK	-11.06	1.67	-1.14	-3.43	-0.38
Shareholders' equity per share
before dilution, SEK	18.02	19.80	19.96	19.58	18.81
after dilution, SEK	18.84	20.45	20.46	20.11	19.27
Average number of shares
before dilution, 000s	93,991	94,136	93,698	93,803	92,437
after dilution, 000s	94,182	94,785	94,249	94,394	92,831
Number of shares at closing
before dilution, 000s	94,028	94,332	93,036	93,766	92,052
after dilution, 000s	95,703	95,703	94,072	94,882	92,976